» Articles » PMID: 18050288

No Mortality After 150 Consecutive Pancreatoduodenctomies with Duct-to-mucosa Pancreaticogastrostomy

Overview
Journal J Surg Oncol
Date 2007 Dec 1
PMID 18050288
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objectives: The mortality rate after pancreatoduodenectomy (PD) remains 0-5% at major surgical centers with the major cause of operative death being a leak at the pancreaticojejunal anastomosis. The aim of this retrospective study was to evaluate the safety of duct-to-mucosa pancreaticogastrostomy (PG) at a single institute.

Methods: One hundred fifty consecutive patients with pancreato-biliary diseases undergoing duct-to-mucosa PG following PD between 1995 and 2005 were evaluated. One hundred forty patients underwent a pylorus-preserving PD and 10 patients underwent a conventional PD (Whipple operation). External drainage of pancreatic juice was performed in 77 cases.

Results: The mean operating time was 378 min and the mean blood loss was 1,640 ml. Blood transfusion was not required in 97 patients (65%). The morbidity rate was 50% (75/150), but the mortality rate was 0%. Pancreatic fistulae occurred in 11 patients (7%). Gender, age, operative procedure, portal vein resection, external drainage of the pancreatic juice, operative time, blood loss and blood transfusion did not affect the rate of pancreatic fistula. The rate of pancreatic fistulae tended to be lower in pancreatic carcinoma (3%) than non-pancreatic carcinoma (11%).

Conclusions: Duct-to-mucosa PG is a safe procedure for reconstruction following PD.

Citing Articles

Computed tomography-based radiomics and body composition analysis for predicting clinically relevant postoperative pancreatic fistula after pancreaticoduodenectomy.

Wu H, Yu D, Li J, He X, Li C, Li S Gland Surg. 2024; 13(9):1588-1604.

PMID: 39421053 PMC: 11480874. DOI: 10.21037/gs-24-167.


Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma.

Sumiyoshi T, Uemura K, Shintakuya R, Okada K, Baba K, Harada T Ann Surg Oncol. 2024; 31(7):4665-4672.

PMID: 38652196 PMC: 11164736. DOI: 10.1245/s10434-024-15221-z.


Prognostic factor in patient with recurrent pancreatic adenocarcinoma.

Sumiyoshi T, Uemura K, Shintakuya R, Okada K, Otsuka H, Baba K Langenbecks Arch Surg. 2023; 408(1):347.

PMID: 37658871 DOI: 10.1007/s00423-023-03073-2.


Prognostic impact of lung recurrence in patients with biliary tract cancer.

Sumiyoshi T, Uemura K, Shintakuya R, Okada K, Serikawa M, Ishii Y Langenbecks Arch Surg. 2023; 408(1):290.

PMID: 37522989 DOI: 10.1007/s00423-023-03015-y.


Hepatic artery resection in distal cholangiocarcinoma.

Sumiyoshi T, Uemura K, Takasaki T, Kondo N, Katayama K, Okada K Langenbecks Arch Surg. 2023; 408(1):58.

PMID: 36688973 DOI: 10.1007/s00423-022-02749-5.